BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shaffer SR, Huang E, Patel S, Rubin DT. Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis. Am J Gastroenterol 2021;116:125-33. [PMID: 32947317 DOI: 10.14309/ajg.0000000000000847] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Yuan W, Marwaha JS, Rakowsky ST, Palmer NP, Kohane IS, Rubin DT, Brat GA, Feuerstein JD. Trends in Medical Management of Moderately to Severely Active Ulcerative Colitis: A Nationwide Retrospective Analysis. Inflamm Bowel Dis 2022:izac134. [PMID: 35786768 DOI: 10.1093/ibd/izac134] [Reference Citation Analysis]
2 Shaffer SR, Rubin DT. Response to Tetangco and Hanauer. Am J Gastroenterol 2021;116:1959-60. [PMID: 34101668 DOI: 10.14309/ajg.0000000000001330] [Reference Citation Analysis]
3 Tetangco EP, Hanauer SB. 5-ASAs Combined With a Biologic or Tofacitinib: Predetermined Cost-Effectiveness? Am J Gastroenterol 2021;116:1958-9. [PMID: 34465697 DOI: 10.14309/ajg.0000000000001296] [Reference Citation Analysis]